Synthesis and Anticonvulsant Activity of 3-Alkyl-3,4-dihydro-2(1*H*)-quinazolinones Milton J. Kornet

Division of Medicinal Chemistry and Pharmaceutics, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0082 Received August 19, 1991

Previously we reported the potent anticonvulsant activity of 3-dimethylamino-3,4-dihydro-2(1*H*)-quinazolinone. In this report, a series of 3-alkyl-3,4-dihydro-2(1*H*)-quinazolinones was synthesized in three steps from isatoic anhydrides or an anthranilic acid. Structure/activity investigations revealed optimal activity for the 3-isopropyl and 3-cyclohexyl analogs. These compounds were effective against seizures induced by maximal electroshock.

J. Heterocyclic Chem., 29, 103 (1992).

In an earlier paper [1] we reported the synthesis and anticonvulsant activity of a series of 3-amino-3,4-dihydro-2(1H)-quinazolinones. The 3-dimethylamino analog V [R_1 , $R_3 = H$, $R_2 = N(CH_3)_2$] exhibited an MES ED₅₀ of 24 mg/kg and a TD₅₀ of 58 mg/kg. These promising results led us to consider quinazolinones V with $R_2 =$ alkyl and cycloalkyl. Such compounds may be considered as isosteric [2] equivalents of the 3-amino-3,4-dihydro-2(1H)-quinazolinones. A literature survey showed that the only known quinazolinones V with 3-alkyl groups were the 3-methyl [3] and 3-ethyl [4] compounds. In this report, we are communicating the synthesis and anticonvulsant activity of a series of 3-alkyl-3,4-dihydro-2(1H)-quinazolinones V. Compound Vh is also included and differs from the other members in that it is 1,3-dialkylated.

A three step synthesis starting from isatoic anhydride (I) was utilized for the preparation of Va-e. The anthranilamides III obtained by reaction of isatoic anhydride with an amine were reduced with sodium bis(2-methoxyethoxy)-

aluminum hydride (SMEAH) to the o-aminobenzylamines IV. Compounds IV were then cyclized to the quinazolinones V by means of ethyl chloroformate/pyridine [1] except that carbonyldiimidazole [5] was used to obtain Va (Scheme I). Because of the unavailability of aromatic ring methylated isatoic anhyrides, an alternate reaction for the first step of the synthesis was used for Vf and Vg. The requisite anthranilamides IIIf-g were obtained by condensing anthranilic acids II with aliphatic amines by means of silicon tetrachloride [6-8] (Scheme I). Compound Vh was synthesized via sodium hydride promoted alkylation of Va with o-fluorobenzyl chloride.

The quinazolinones (Table I) were tested in the maximal electroshock (MES) seizure and pentylenetetrazol (sc Met) seizure threshold tests for anticonvulsant activity and neurotoxicity in mice by known methods [9]. In the MES test, compounds Vc and Ve showed activity at 100 mg/kg at 30 minutes with no toxicity. Compounds Va, Vb, Vd and Vf showed activity at 100 mg/kg at 30 minutes but were toxic

Table I

Physical Properties of 3,4-Dihydro-2(1H)-quinazolinones

Compound	$\mathbf{R_1}$	R_2	R_3	Melting	Yield	Formula	Analysis, % Calcd./Found		
•	-	-	Ū	Point, °C	%		C	H	N
Va	Н	$\mathrm{CH_3}$	Н	200-203 [a]	46	$C_9H_{10}N_2O$			
Vb	\mathbf{H}	C_2H_5	\mathbf{H}	146-147 [b]	61	$C_{10}H_{12}N_2O$			
Ve	H	$(CH_3)_2CH$	H	171.5-172 [c]	63	$C_{11}H_{14}N_2O$	69.45	7.42	14.72
							69.74	7.41	14.92
Vd	H	c -C $_5$ H $_9$	\mathbf{H}	156-158 [c]	75	$C_{13}H_{16}N_2O$	72.19	7.46	12.95
							72.25	7.33	12.93
Ve	H	$c\text{-}\mathrm{C_6H_{11}}$	H	189-191 [c]	63	$C_{14}H_{18}N_2O$	73.01	7.88	12.16
							73.30	7.76	12.42
Vf	\mathbf{H}	$\mathrm{CH_3}(\mathrm{CH_2})_2$ -	8-CH ₃	111-112 [d]	59	$\mathrm{C_{12}H_{16}N_2O}$	70.56	7.90	13.71
							70.66	8.18	13.80
Vg	\mathbf{H}	$c ext{-}\mathrm{C_6H_{11}}$	6-CH ₃	193-195 [c]	61	$\mathrm{C_{15}H_{20}N_{2}O}$	73.74	8.25	11.46
							73.84	8.49	11.53
Vh	$o ext{-}\mathrm{FC}_6\mathrm{H}_4\mathrm{CH}_2$	CH_3	Н	121-122 [e]	88	$C_{16}H_{15}FN_2O$	71.10	5.59	10.36
							71.15	5.32	10.57

[a] Reference [3] reported mp 198-202. [b] Reference [4] reported mp 146-148. [c] Aqueous ethanol. [d] Petroleum ether (bp 35-56°)-hexane.

at this dose. Compound Vh exhibited activity at 300 mg/kg (30 minutes, no toxicity). In the sc Met test, Vb and Vf were active at 100 mg/kg but also toxic. Compounds Va, Vc, Vd, Ve, and Vh were active at 300 mg/kg and with the exception of Ve also toxic.

The single inactive compound (300 mg/kg) in both tests was Vg. Compound Vc was submitted for Phase II testing and exhibited an MES ED₅₀ value of 32 mg/kg, sc Met ED₅₀ value of 72 mg/kg and TD₅₀ value of 78 mg/kg. This compound, therefore, shows activity and toxicity comparable to that of the isosteric 3-dimethylamino-3,4-dihydro-2(1H)-quinazolinone [1].

EXPERIMENTAL

Melting points were determined on either a Thomas-Hoover or Fisher-Johns melting point apparatus and are uncorrected. The ir spectra were taken on a Perkin-Elmer 1430 spectrophotometer as liquid films or potassium bromide pellets. The nmr spectra were recorded on a Varian XL-200 spectrometer using tetramethylsilane as the internal reference. Mass spectra were obtained on an RMU-7 double focusing spectrometer by Hitachi/Perkin-Elmer. Elmental analyses were performed by Baron Consulting Co., Orange, CT.

N-Cyclopentylanthranilamide (IIId).

A solution of 9.37 g (0.11 mole) of cyclopentylamine in 15 ml of methylene chloride was added dropwise to 8.15 g (0.05 mole) of isatoic anhydride in 45 ml of methylene chloride with stirring (magnetic). After standing overnight, chloroform was added to attain solution. The organic phase was washed twice with 60 ml of 5% sodium carbonate solution. The aqueous phase was extracted with chloroform and the combined organic phase was dried (magnesium sulfate). The solvent was evaporated at reduced pressure

and the solid residue was recrystallized from toluene and afforded 8.31 g (81%) of a white solid, mp 157-158°; 'H nmr (deuteriochloroform): δ 1.3-2.25 (m, 8H), 4.2-4.5 (m, 1H), 4.8-6.3 (two broad s, 3H), 6.45-6.8 (m, 2H), 7.0-7.4 (m, 2H).

N-(o-Aminobenzyl)cyclopentylamine (IVd).

To a stirred mixture of 50 ml of 70% sodium bis(2-methoxyethoxy)aluminum hydride in toluene and 50 ml of toluene was added 4.5 g (0.022 mole) of **IIId** portionwise over a period of 15 minutes. The mixture was refluxed overnight, cooled to room temperature, and added dropwise to 80 ml of a stirred, cooled solution of 20% sodium hydroxide. The organic layer was separated and the aqueous layer was extracted twice with toluene. The combined toluene extract was dried (magnesium sulfate) and concentrated to 4.17 g of oily diamine which was used directly in the next step.

3-Cyclopentyl-3,4-dihydro-2(1H)-quinazolinone (Vd).

To a stirred and ice-bath cooled solution of 4.17 g (0.0219 mole) of the above oily diamine in 20 ml of dry pyridine was added dropwise 2.73 g (0.0252 mole) of ethyl chloroformate. The mixture was stirred overnight at room temperature and then refluxed for 24 hours (nitrogen atmosphere). The reaction mixture was poured into 100 ml of ice-water and gave a yellow solid which was filtered and washed well with water. Recrystallization from aqueous ethanol afforded 3.56 g (75%) of golden cyrstals, mp 156-158°; 'H nmr (deuteriochloroform): δ 1.54-1.98 (m, 8H), 4.32 (s, 2H), 4.86-5.04 (m, 1H), 6.74-7.22 (m, 4H), 8.50-8.76 (m, 1H).

2-Amino-3-methyl-N-propylbenzamide (IIIf).

A solution of 4.54 g (0.03 mole) of 2-amino-3-methylbenzoic acid, 2.13 g (0.036 mole) of propylamine and 80 ml of pyridine was cooled in an ice-water bath. Silicon tetrachloride (6.1 g, 0.036 mole) was added dropwise with stirring (magnetic) over 30 minutes under nitrogen. After stirring at room temperature for 2 hours, the mixture was refluxed for 6.25 hours. The mixture was

[[]e] Toluene-hexane.

poured onto ice with stirring and evaporated in vacuo to remove the pyridine as a pyridine-water azeotrope. Water was added and the mixture was evaporated in vacuo a second time. The residue (hydrochloride salt of the product) was basified with aqueous sodium carbonate solution and extracted three times with ether in a separatory funnel. Care was exercised to exclude the heavier silica particles each time. The combined ether extracts were dried (magnesium sulfate) and evaporated yielding 3.76 g (65%) of product, mp 99-101°; 'H nmr (deuteriochloroform): δ 0.90-1.1 (t, 3H), 1.45-1.76 (m, 2H), 2.17 (t, 3H), 3.38 (q, 2H), 5.0-5.89 (broad s, 2H), 5.90-6.27 (broad s, 1H), 6.60 (t, 1H), 7.03-7.32 (dd, 2H). Because filtration of silica is avoided, this procedure is simpler than the one previously reported [8].

2-Amino-5-methyl-N-cyclohexylbenzamide (IIIg).

This compound was prepared similarly to **IIIf** from 4.54 g (0.03 mole) of 5-methylanthranilic acid, 2.98 g (0.03 mole) of cyclohexylamine, 6.1 g (0.036 mole) of silicon tetrachloride in 82 ml of pyridine. Workup afforded 2.52 g (36%) of white solid, mp 205-206°; ¹H nmr (deuteriochloroform): δ 1.08-2.08 (m, 10H), 2.23 (s, 3H), 3.82-4.01 (m, 1H), 4.8-5.6 (broad s, 2H), 5.7-6.1 (d, 1H), 6.60 (d, 1H), 7.01 (d, 1H), 7.08 (s, 1H).

1-(o-Fluorobenzyl)-3-methyl-3,4-dihydro-2(1H)-quinazolinone (**Vh**).

To a stirred mixture of 0.50 g (0.0031 mole) of Va, 0.20 g of sodium hydride (60% in mineral oil) and 4.0 ml of dry dimethyl sulfoxide was added dropwise 0.493 g (0.00341 mole) of o-fluorobenzyl chloride. The mixture was stirred for twenty hours at room temperature. Dilution with ice-water produced a pale yellow precipitate which was filtered. Recrystallization from aqueous ethanol gave 0.74 g (88%) of product, mp 118.5-121.5°. The analytical sample was obtained from toluene-hexane, mp 121-122°; 'H nmr (deuteriochloroform): δ 3.09 (s, 3H), 4.45 (s,

2H), 5.17 (s, 2H), 6.65 (d, 1H), 6.84-7.34 (m, 7H). 3-Methyl-3,4-dihydro-2(1H)-quinazolinone (Va).

To a solution of 2.77 g (0.0204 mole) of 2-amino-N-methylbenzylamine [3] in 25 ml of tetrahydrofuran was added 4.12 g (0.0255 mole) of carbonyldiimidazole. The mixture was stirred at room temperature for one hour, refluxed for 19 hours, and poured into 200 ml of water. The precipitate was filtered, dried and after recrystallization from ethyl acetate afforded 1.52 g (46%) of product, mp 200-203° [lit [3] mp 198-202°]; 'H nmr (deuteriochloroform): δ 3.04 (s, 3H), 4.44 (s, 2H), 6.73-7.20 (m, 4H), 8.55 (s, 1H). Acknowledgement.

The author is grateful to the Antiepileptic Drug Development Program, National Institutes of Health, for providing the pharmacological data and to Karen Blumenschein for assistance in a part of the synthetic work.

REFERENCES AND NOTES

- [1] M. J. Kornet, T. Varia and W. Beaven, J. Heterocyclic Chem., 21, 1709 (1984).
- [2] J. H. Block in Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, J. N. Delgado and W. A. Remers, eds, Ninth Ed, J. B. Lippincott, Philadelphia, PA, 1991, p 30.
 - [3] M. R. Boots and S. G. Boots, J. Med. Chem., 13, 144 (1970).
- [4] C. Bogentoft and B. Danielsson, Acta Pharm. Suecica, 7, 257 (1970).
 - [5] W. E. Coyne and J. W. Cusic, J. Med. Chem., 11, 1208 (1968).
 - [6] T. H. Chan and L. T. L. Wong, J. Org. Chem., 34, 2766 (1969).
 - [7] T. H. Chan and L. T. L. Wong, J. Org. Chem., 36, 850 (1971).
- [8] M. J. Kornet, T. T. Tita and A. P. Thio, Synth. Commun., 16, 1261 (1986).
 - [9] M. J. Kornet, J. Pharm. Sci., 67, 1471 (1978).